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Abstract
Rationale: The adult myocardium has been reported to harbor several classes of multipotent progenitor cells (CPCs) with
tri-lineage differentiation potential. It is not clear whether c-kit+CPCs represent a uniform precursor population or a more
complex mixture of cell types.
Objective: To characterize and understand vasculogenic heterogeneity within c-kit+presumptive cardiac progenitor cell
populations.
Methods and Results: c-kit+, sca-1+ CPCs obtained from adult mouse left ventricle expressed stem cell-associated genes,
including Oct-4 and Myc, and were self-renewing, pluripotent and clonogenic. Detailed single cell clonal analysis of 17
clones revealed that most (14/17) exhibited trilineage differentiation potential. However, striking morphological differences
were observed among clones that were heritable and stable in long-term culture. 3 major groups were identified: round (7/
17), flat or spindle-shaped (5/17) and stellate (5/17). Stellate morphology was predictive of vasculogenic differentiation in
Matrigel. Genome-wide expression studies and bioinformatic analysis revealed clonally stable, heritable differences in
stromal cell-derived factor-1 (SDF-1) expression that correlated strongly with stellate morphology and vasculogenic
capacity. Endogenous SDF-1 production contributed directly to vasculogenic differentiation: both shRNA-mediated
knockdown of SDF-1 and AMD3100, an antagonist of the SDF-1 receptor CXC chemokine Receptor-4 (CXCR4), reduced tube-
forming capacity, while exogenous SDF-1 induced tube formation by 2 non-vasculogenic clones. CPCs producing SDF-1
were able to vascularize Matrigel dermal implants in vivo, while CPCs with low SDF-1 production were not.
Conclusions: Clonogenic c-kit+,s c a - 1 + CPCs are heterogeneous in morphology, gene expression patterns and
differentiation potential. Clone-specific levels of SDF-1 expression both predict and promote development of a
vasculogenic phenotype via a previously unreported autocrine mechanism.
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Introduction
Heart failure is a lethal and disabling end result of a number of
highly prevalent cardiovascular diseases, including hypertension
and coronary atherosclerosis, and is estimated to affect 2.8% of the
present US population[1]. Although current trends show some
improvement in heart failure-specific mortality [2,3,4], the
predicted 25% increase in heart failure by the year 2030 will pose
a major therapeutic challenge. Recent basic research studies have
shown that myocyte loss plays a major role in the induction and
progression of most if not all forms of heart failure [5,6,7,8,9,10]. In
parallel, studies have revealed that many adult tissues, notably bone
marrow, but also skeletal muscle, synovium and adipose tissue,
contain self-renewing, pluripotent cells capable of repairing injured
myocardium and/or improving blood flow to the heart ([11,12,
13,14], reviewed in [15]). These insights have led to a rapid and
intensive pursuit of regenerative strategies to increase the number of
functional cardiac myocytes and blood vessels in the damaged and
failing myocardium (reviewed in[16,17,18,19,20,21]). In the last 5
years, clinical trials have shown myocardial delivery of stem cells
from bone marrow and other sources to be safe and effective in
improving clinical outcomes, with generally favorable effects on left
ventricular function[22,23,24,25,26,27]; further large randomized
trials are continuing [28,29,30]. However, significant controversy
remains. Among other issues, there is no agreement on the
mechanism of action of stem cell therapy, nor on the optimal
method, dose and timing of their delivery; the best source of
reparative cells also has yet to be established[31,32,33,34].
PLoS ONE | www.plosone.org 1 August 2011 | Volume 6 | Issue 8 | e24013The adult myocardium has recently been shown to harbor
multipotent progenitor cells that can give rise to both myogenic
and vasculogenic lineages, and that have been shown to contribute
to myocardial repair [11,35,36,37,38]. Several different types of
cardiac precursor cells (CPCs) have been described, distinguished
by method of isolation and/or expression of surface markers,
including c-kit, stem cell antigen (sca-1), transporter protein
ABC1, and transcription factor islet-1 (Isl1). Each of these has
been reported to be self-renewing, to differentiate along three
major myocardial lineages (cardiac myocytes, smooth muscle and
endothelial cells) [11,39,40,41,42,43,44,45,46], and to be capable
of reconstituting injured myocardium [11,13,39,42,47,48,49].
Despite the greater accessibility of other progenitor cell types,
cardiac-derived stem cells have excited considerable therapeutic
interest, because of their greater potential for cardiomyogenic
differentiation, engraftment and survival within the myocardi-
um[34], and the potential of endogenous CPCs to respond to
exogenous or paracrine mobilization signals. However, the clinical
application of CPCs remains limited by substantial uncertainty
over how to define, isolate and expand an optimum cell type for
transplantation, and more fundamentally by a need to understand
the origins and biological properties of various CPC populations
[9,11,50,51,52].
In this study, we performed single cell cloning to study the
properties of one type of cardiac progenitor cell: sca-1+, c-kit+CPCs
derived from the left ventricles of adult mouse hearts. We show that
thesecellsexhibitasurprisingdegreeofclonallystableheterogeneity
in morphology, gene expression and functional properties, and
importantly, in the potential for vasculogenic differentiation. We
find that a major component of this heterogeneity is clonal variation
in endogenous expression of the chemokine SDF-1, which in turn
controls the morphology and vasculogenic potential of CPCs. We
conclude that SDF-1 may serve both as a biomarker and an effector
of CPC therapeutic potential.
Results
Isolation of clonogenic cardiac progenitor cells (CPCs)
Sca-1+cells were isolated from the left ventricles of adult mice
expressing a GFP transgene under the human ubiquitin C (UBC)
promoter (C57BL/6-tg(UBC-GFP)30Scha) and cultured in bacte-
rial Petri dishes for 2-days, after which cell aggregates grown in
suspension were transferred to tissue culture plates and expanded
(Fig. 1A–C). Cells at this stage were positive for both Sca-1 and c-
kit (Fig. 1D). Expression of the embryonic stem cell marker Oct4
was readily detected (Figure 1E) and similar to that seen in P19
teratocarcinoma cells (Figure 1F). Serial dilution cloning was used
to obtain 65 single cell clones, of which 17 have now been ex-
panded up to 60 times without evidence of senescence, confirming
a significant self-renewal capacity. Doubling time was ,24–48 h
for all clones (Figure S1). 17 low passage (P8–P23) clones were
selected for further characterization.
CPCs are morphologically heterogeneous
Cells from the initial isolate exhibited morphological heteroge-
neity (Figure 1B), falling broadly into 3 categories: spindle and flat,
stellate, and small and round, in roughly equal proportions
(Figure 2). Stellate cells had multiple cellular projections of varying
lengths that occasionally ramified. Small, round clones had few
visible cellular projections and a high nucleus:cytosol ratio. Cell
volumes in suspension varied little, however (data not shown),
suggesting that the observed differences in shape were related to
cell-matrix attachments. In all cases, cell morphology was a
clonally stable trait that did not change with serial passage.
CPC clones differ in their commitment to endothelial and
muscle lineages
After 2–4 weeks of differentiation in low mitogen medium, all
CPC clones exhibited mesodermal pluripotency, and differentiated
in varying proportions along smooth muscle, cardiomyogenic
and/or endothelial lineages (Figure 3). 2 clones differentiated along
endothelial and cardiac lineages only, and 1 expressed endothelial
and smooth muscle but not cardiac markers (see Table 1); the
remainder displayed trilineage potential. Cardiac muscle proteins
troponin I, desmin, myosin heavy chain and sarcomeric a-actin
were induced in some cells (Figure 3A–D), although well-organized
sarcomeres and contractile activity were not observed. Some clones
gave rise to greater numbers of large, flat cells expressing smooth
muscle actin (SMA) organized into filaments (Figure 3F, G), relative
to others (Figure 3E). In some of these large cells, SMA co-localized
withthe smooth muscle marker SM22-a, whilein others, expression
appeared to be mutually exclusive (compare Figures 3E, F). Most
sarcomeric a-actin+ and some SMA+ cells co-expressed GATA4
(Figure 3D, G). All clones contained FLK1+ cells (Figure 3H), both
before and after differentiation, and a smaller number of cells
expressed von Willebrand Factor (vWF, Figure 3I), supportive of
endothelial differentiation.
Morphology, but not FLK-1 expression, identifies CPC
subpopulations with enhanced vasculogenic potential
To further characterize the differentiation potential of individ-
ual clones, induction of lineage marker gene expression was
followed over a 4-week period after LIF withdrawal in 16 clones.
Consistent clone-specific variations were observed in the timing
and quantity of induced lineage marker mRNAs (Figure 4A).
When lineage marker expression patterns were analyzed using an
unbiased hierarchical clustering algorithm, clones were grouped
into 2 main clusters, one of which showed greater induction of
FLK-1, and the other greater induction of SMA and to a lesser
extent GATA4 (Figure 4B). 4 out of 5 stellate clones fell within the
second cluster (Figure 4B, *). Surprisingly, FLK-1 expression was
not required for functional vasculogenic competence. Multiple
clones from both expression groups underwent efficient endothe-
lial differentiation and capillary tube formation in a 3D Matrigel
assay (Figure 4B). Moreover, FLK-1 expression was not sufficient
for effective vasculogenesis, as some FLK-1-inducing clones were
only weakly vasculogenic (Figure 4B, below right). Clones with
stellate morphology tended to be strongly vasculogenic; most
formed tubes at a rate similar to that of human umbilis (Figure 4B,
below left), and more rapidly than the other clone types (28.262.5
vs. 17.564.0 tubes/field/5 h, p=0.04).
SDF-1 expression levels predict CSC morphology
In searching for other features that could identify clones with
enhanced vasculogenic differentiation, we performed gene ex-
pression profiling on a group of 5 undifferentiated clones repre-
senting each morphological group (Figure 5). As expected, a
focused real-time PCR array of 84 stem cell-related genes showed
that 30 were expressed at high levels in each of 6 clones
examined, although some heterogeneity was noted, particularly
in expression of SDF-1 (Figure 5A). We then performed
Affymetrix microarray expression profiling of 3 of these clones
plus an additional 2, which confirmed overall similarity in gene
expression profiles, with relatively few transcripts showing
significant differential expression among clones (Figure 5B; data
deposited in GEO database, record # GSE24828). When clones
were grouped by gene expression patterns using the same
unbiased hierarchical algorithm, the 2 spindle-shaped clones
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segregated from the other 4, whether all 39,000 genes from the
Affymetrix array (Figure 5B) or the subset of stem cell genes
(Figure 5C) was used. These results supported an association
between gene expression and cell morphology.
To refine the search, we conducted additional hierarchical
clustering on subsets of genes defined by biological process terms
from Gene Ontology (GO) (http://www.geneontology.org/). 14
GO biological processes, including cell adhesion, microtubule
stabilization, and nitric oxide-mediated signal transduction
Figure 1. Cardiac progenitor cells express stem cell markers. A. Cardiosphere 24 hours after CPC isolation. B. Morphologically heterogeneous
parental CPC isolate. C. CPC colony used for initial clonal expansion. D. CPCs stained for stem cell markers Sca-1 and c-Kit, counterstained with DNA
dye DAPI to reveal nuclei. E–F. CPCs (E) and P19 teratocarcinoma cells (F) expressing Oct4 (green). Original magnification A–D: 32x. Original
magnification E, F: 100x.
doi:10.1371/journal.pone.0024013.g001
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PLoS ONE | www.plosone.org 3 August 2011 | Volume 6 | Issue 8 | e24013Figure 2. Clonal variation in CPC morphology. Single cell CPC clones from the original isolate showed clonal, stable differences in shape, size,
and nucleus/cytosol ratio. Shown are CPC clones representing 3 basic phenotypes: small and round (CL1D and CL20B), stellate (CL11B and CL42A1),
and spindle/flat (CL13 and CL30C1).
doi:10.1371/journal.pone.0024013.g002
Figure 3. Trilineage differentiation of cardiac progenitor cells. CPCs 4 weeks after differentiation stained with antibodies against cardiac,
smooth muscle and endothelial markers as shown. A. TNI. B. Desmin. C. MHC. D. sarcomeric actin (SA) and GATA4. E, F. SMA and SM22-a. G. SMA and
GATA4. H. Flk-1/KDR. I. vWF. For images A–C, E-H: original magnification 32X. Images D, I: original magnification 100X. Shown are clones 1D (A, D),
20B (E) and 11B (B, C, F–H).
doi:10.1371/journal.pone.0024013.g003
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In particular, stellate morphology was closely associated with
elevated expression of SDF-1a and -b isoforms (GO term ‘‘germ
cell migration’’; Figure 5D and Table S1).
Autocrine SDF-1 production determines CPC
vasculogenic properties
We reasoned that SDF-1 could be a common driver both of the
stellate morphology and of enhanced tube-forming capacity in
Matrigel. To determine the relationships among SDF-1, mor-
phology and vasculogenic potential, we measured pre-differenti-
ation SDF-1 and Flk-1 protein in the 12 previously analyzed clones
(see Figure 4) and correlated them with quantitative measures of
tube formation in Matrigel. SDF-1 protein levels correlated well
with tube length and number (r=0.67) (Figure 6A; see also
Table 1). In contrast, FLK-1 protein levels varied widely, from
nearly undetectable to high, comparable to HUVECs, but did not
correlate with vasculogenic capacity (r=0.24) (Figure S2).
We next sought to validate the apparent correlation between
endogenous SDF-1 production and tube formation, and determine
its mechanistic significance. Stable lentivirus-mediated shRNA
transfection was used to knock down SDF-1 in one of the highest-
expressing clones, CL11B. 45–50% reduction in SDF-1 was
achieved by each of 3 different targeting shRNAs (Figure S3). In
each case, partial SDF-1 loss resulted in significant reduction in
tube length, relative to clones transduced with a non-silencing
shRNA (p#0.05, Figure 6B).
CPC clones were next treated with SDF-1 or AMD3100, an
antagonist of the receptor for SDF-1, CXCR4. As predicted,
exogenous SDF-1 promoted tube formation in all poorly
vasculogenic clones tested, for example CL3 (control vs. SDF,
8.3861.48 vs. 15.161.46 tubes/HPF, n=15, p ,0.005) and
CL20 (9.3061.8 vs. 20.363.6, n=5, p,0.01, S.E.M.) (Figure 6C).
Correspondingly, treatment with AMD3100 impaired tube
formation in strongly vasculogenic clones, including CL22 (control
vs. AMD, 18.462.1 vs. 10.861.2, n=10, p,0.01) and CL42A1
(16.161.8 vs. 8.2060.10, n=10, p,0.01) in a manner that was
reversed by exogenous SDF-1 (CL22: AMD vs. AMD+SDF-1,
10.861.2 vs. 22.861.5, n=10, p,0.001; CL42A1: 8.2060.10 vs.
14.261.8, n=10, p,0.05) (Figure 6C). Similar results were
obtained with CL17 and CL30C1 (not shown).
CPC SDF-1 promotes vasculogenesis in dermal implants
in vivo
To further validate these findings, we performed an in vivo assay
in which Matrigel inserts were implanted subdermally for one
week in congenic C57Bl/6 mice. Matrigel inserts alone (Figure 7A,
D), or containing cells from the low SDF-1/non-stellate/weak
tube-forming clone 30C1 (Figure 7B, E), were not vascularized.
However, inserts with cells from high SDF-1/stellate/strong tube-
forming clone 11B reproducibly acquired multiple blood vessels
that were continuous with the host circulation (Figure 7C, F-I;
Figure S4). Portions of the formed blood vessels within the insert
were positive for GFP (Figure 7H, I), indicating a contribution of
the GFP transgene-labelled CPCs to these structures. These
findings are consistent with our previous findings in vitro, and
support the view that endogenous SDF-1 production by CPCs
enhances their vasculogenic differentiation potential in vivo, as well
as anastomosis with host-derived blood vessels.
Discussion
In the adult myocardium, primitive cells capable of regenerating
myocytes and, to a lesser extent, resistance coronary arterioles and
capillaries in vivo in response to injury have been identified using
several different surface markers and isolation techniques[51,53,54,55].
Table 1. Summary of morphological, self-renewal and vasculogenic properties of cardiac progenitor cell clones.
Clone Morphology Last Passage # Lineage differentiation Vasculogenic index SDF-1 Levels pg/ml
Cardiac Smooth muscle Endo-thelial
CL1D small/round 48 2 ++ 17.80 19.09
CL3 flat/spindle 23 ++ + 9.11 12.85
CL6 small/round 10 ++ + ND ND
CL7 flat/spindle 49 + 2 + ND ND
CL11B stellate 60 ++ + 23.96 157.82
CL13 flat/spindle 38 + 2 + 14.50 59.40
CL17 stellate 15 ++ + 21.92 131.57
CL19 small/round 17 ++ + ND ND
CL20 small/round 15 ++ + 5.90 29.96
CL20B small/round 50 ++ + 7.91 37.50
CL22 stellate 15 ++ + 19.40 202.61
CL23 small/round 15 ++ + 18.19 54.12
CL25 stellate 11 ++ + ND ND
CL27 flat/spindle 14 ++ + ND ND
CL30C1 flat 54 ++ + 1.97 15.82
CL32 small/round 15 ++ + 16.80 45.06
CL42A1 stellate 41 ++ + 9.82 84.91
Morphology was assessed by light microscopy and immunocytology. Last passage number: maximum number of passages to date. Vasculogenic index: lengthx
number of tubes formed per high power field in Matrigel at 5 hours. SDF-1 levels were determined by ELISA (see Methods).
doi:10.1371/journal.pone.0024013.t001
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expression of Sca-1+ and c-Kit+, described by other groups
[11,42,45,49], are pluripotent as defined by induction of distinct
lineage markersinindividualprogenyduringinvitrodifferentiation,
and clonogenic, indicating that they represent a true progenitor
population. In addition, using single cell clonal analysis, we reveal
that these cells comprise multiple subpopulations exhibiting
substantial heterogeneity in gene expression profile, morphology
and lineage preference, particularly in acquisition of a functional
vasculogenic phenotype. Finally, we provide a molecular basis for
part of this variability by demonstrating inherent differences in
expression of the chemokine SDF-1 that drives morphological and
functional angiogenic differentiation. This observation is important
because the ability of CPCs to form vascular structures is likely to be
key to the support of cell survival and engraftment in the ischemic
myocardium, and therefore to their therapeutic usefulness. Our
data indicate that SDF-1 expression may be an important way to
qualify the angiogenic potential of therapeutic cell isolates for
cardiovascular disease.
Vessel wall-resident progenitor cells have been documented in a
number of adult tissues, including the bone marrow, skeletal
muscle and adipose tissue, and give rise to both endothelial and
smooth muscle cells that contribute to post-natal angiogenesis and
tissue repair[56]. Recently, a c-kit+ presumptive coronary artery
progenitor population was identified by Bearzi et al within the
coronary artery wall, that was able to regenerate larger (1.5 mm)
resistance vessels and contribute to improved myocardial blood
flow in a dog model of ischemia[52]. The cells described here are
distinct from the latter, based both on site of isolation (muscle vs.
blood vessel) and surface expression of Flk-1/KDR, a defining
feature of the coronary stem cell that was highly variable in our
cell populations.
Phenotypic heterogeneity has been previously noted in primary
isolates of mesenchymal stem cells from bone marrow and
synovium as well as in myocardial progenitor cells [11,57,58]. It
is not clear whether this diversity indicates the presence of multiple
unrelated cell populations or different stages of differentiation in a
single primitive cell type. Our single cell clonal analysis provides a
Figure 4. Heterogeneous differentiation of CPC clones. A. Heat map showing clonal heterogeneity in timing and level of induction of lineage
markers during differentiation. Absolute values of each mRNA expressed in log2 scale. B. Peak marker gene expression levels were used for
unsupervised hierarchical clustering. * stellate, + efficient and (2) weak tube formation. Below: Clones 42A1 (efficient) and 20B (weak) after 5 h in
Matrigel.
doi:10.1371/journal.pone.0024013.g004
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the differences in shape are clonally stable and likely dictated by
differences in substrate attachment and spreading properties, as
cell volumes are essentially identical. Second, although gene
expression patterns were generally highly similar, clonally stable
differences in expression of specific genes could be demonstrated,
possibly reflecting changes acquired by the progeny of a single
parental cell type. Cell morphology can be decisively influenced by
differences in expression of a few genes, for example, those
involved in cytoskeletal organization [59]. Thus, it is plausible that
minor clonal changes in the epigenome of progenitors, perhaps
linked to local tissue signals, could lead to substantial phenotypic
heterogeneity.
SDF-1 (also known as CXCL12) is a chemokine that plays an
important role in immune cell attraction, stem cell homing and
cancer metastasis [60,61,62,63,64]. Importantly, SDF-1 also has
a direct role in angiogenesis and vasculogenesis[65] and is
constitutively expressed by endothelial cells as well as stromal
cells from a number of tissues, neural cells and osteoblasts[60,66].
Loss of SDF-1 or its receptors CXCR4 and CXCR7 leads to
defects in vascular development and formation [67,68,69]. SDF-1
promotes vascular morphogenesis and sprouting of endothelial
cells[66,70,71,72] as well as vascular sprouting from embryoid
bodies and aortic rings [73,74]; SDF-1-CXCR4 signalling plays a
critical role in tumor angiogenesis in vivo[75,76]. SDF-1 promotes
de novo vasculogenesis by enhancing the survival, migration,
engraftment and differentiation of endothelial precursor cells
[77,78,79], and supports therapeutic progenitor cell function in
the treatment of myocardial ischemia[80,81]. Paracrine production
of SDF-1 by ischemic myocardium has been shown to promote
blood vessel formation by implanted c-kit+ CPCs in vivo[82]. SDF-1
is thus able to promote angiogenic differentiation in all cell lineages
capable of giving rise to endothelium, both in vitro and in vivo.
Previous reports have described the source of SDF-1 as
exogenous to the differentiating cell [79,83]. Our data suggest
an autocrine role for SDF-1 in promoting endothelial differenti-
ation of CPCs that is independent of signals from other cells. The
mechanism by which intracellular or paracrine SDF-1 interacts
with other differentiation signals remains to be determined. SDF-1
may exert proangiogenic effects by inducing VEGF expression
[79,84], activating NO production [78,85], or initiating a heme
oxygenase-dependent signal[74]. Microarray analysis did not
reveal significant variations in HIF-1 or VEGF transcripts in
undifferentiated CPCs; we also did not find differences in CXCR4
expression, excluding receptor autoregulation or broader upregu-
lation of HIF-1 targets[86,87,88]. VEGF is reported to induce
SDF-1 expression[66], and HIF-1 is a direct regulator of SDF-1
[83], however the lack of clonal variation in these factors means
that other epigenetic mechanisms are likely to be responsible for
the observed differences in SDF-1 expression among individual
progenitor cells.
Although the source of variability remains to be determined, we
show here that high endogenous production of SDF-1 promotes
vasculogenic differention and vascularization in vivo by CPCs, via
a previously unreported autocrine mechanism. SDF-1 may be a
useful biomarker for CPCs with enhanced potential for tissue
revascularization and a tool for improving vasculogenesis in
regenerative cell therapy.
Figure 5. Gene expression associations with morphology. A. Heat map of absolute mRNA expression of stem cell related genes in 6
representative CPC clones. B and C. Clustering by expression levels of (B) all 45,000 genes from array and (C) subset of 84 stem cell-associated genes.
D. Clustering by expression of genes in Gene Ontology (GO) ‘‘germ cell migration’’. Below: Representative images of stellate, spindle and flat
morphologies.
doi:10.1371/journal.pone.0024013.g005
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Materials
Antibodies directed against the following antigens were used to
characterize CPCs: Sca-1 (eBioscience); c-Kit, GATA4, troponin I,
desmin and vWF (Santa Cruz Biotechnology); smooth muscle actin
(Sigma); Flk1 (Cell Signaling); sm22-a and Oct4, (Abcam); Alexa
Fluor 488- or 568-conjugated secondary antibodies (Invitrogen).
Lipofectamine 2000 (Invitrogen) was used for transfection of 293T
cells with viral packaging constructs pCMV-VSV-G and pCMV
delta R8.2 (AddGene) and lentiviral pGIPZ vectors encoding anti-
SDF-1 shRNA or scrambled non-silencing shRNA (Open Biosys-
tems). For RNA analyses we used the Stem Cell RT2 Profile PCR
Array (SABiosciences, Frederick, MD) or standard TaqMan assays
(Applied Biosystems). SDF-1 was purchased from R&D Systems.
C57/BLKS mice were obtained from Jackson Laboratories.
Standard, growth factor-reduced, and high concentration Matrigel
basement membrane matrices were obtained from BD Biosciences.
Except as noted, all other reagents were obtained from Sigma and
were of the highest quality obtainable.
CPC isolation
All animal procedures were performed according to protocols
approved by the University of Miami Institutional Animal Care
and Use Committee (#08-202, 08-060, 07-194). 5–6 month old
C57 Bl/6 mice were sacrificed, hearts were removed and
immediately placed in isolation media (IM) consisting of minimum
essential medium (MEM) and penicillin/streptomycin. After
careful dissection of the left ventricles, the chambers were gently
flushed to remove red blood cells and then cut in 4 parts. Pieces
were finely minced in 2 ml of fresh IM, and transferred to a 50 ml
centrifuge tube containing 5 ml of pre-warmed 567 U/ml
collagenase II (Worthington). Tissues were digested for 30 minutes
at 37uC with shaking. The digestion was stopped by addition of
Figure 6. Autocrine SDF-1 signaling determines vasculogenicity of CPC clones in vitro. A. Correlation between SDF-1 expression and
vasculogenic potential in Matrigel. B. SDF-1 knockdown reduces CPC tube length in Matrigel. Clones were stably transfected with one of three
different SDF-1 shRNAs (D8, E1 and H7) or a scrambled control (NS). C. Exogenous SDF-1 increased mean tube number in both weak (CL3 and CL20)
and strong (CL22 and 42A1) tube forming clones, and AMD3100 decreased tube number in strong tube formers (CL22, CL42A1). Dots represent single
field counts; n=5–15 field counts per clone. *p,0.05, **p,0.01, #p,0.001; n.s. = not significant.
doi:10.1371/journal.pone.0024013.g006
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Undigested heart pieces were allowed to settle, and the
supernatant containing CPCs was separated and filtered through
a7 0mm mesh strainer.
CPC growth and cloning
After estimation of cell number, 1610
7 cells/ml were incubated
with biotin-conjugated anti-Sca-1 antibody for 20 minutes at 4uC
in separation buffer (PBS, 0.1% BSA, 2 M EDTA, pH 7.4). Cells
were washed 2X and incubated with streptavidin-coated magnetic
beads (Dynabeads, Invitrogen Life Science) for 20 minutes at 4uC
in separation buffer prior to magnetic sorting according to the
manufacturer’s instructions. Freshly isolated CPCs were plated in
60 mm bacterial Petri dishes to allow the formation of cardio-
spheres in CPC medium consisting of F12 medium supplemented
with 10% fetal bovine serum (FBS), 10 ng/ml bFGF, 20 ng/ml
EGF, 10 ng/ml LIF, 0.5X ITS supplement and antibiotics. After
24–48 h the suspension was distributed into 24 well culture plates
and cardiospheres were allowed to attach. All wells were checked
daily for proliferating cells. Proliferating CPCs were expanded by
gradual transfer from smaller to larger culture dishes. CPCs were
initially cloned using cloning rings and then subcloned 1–2 times
by serial dilution in 96 well plates. Cell volumes were determined
using a Coulter counter (Beckman Coulter).
CPC differentiation
CPC clones were induced to differentiate by plating cells on
gelatin-coated culture dishes in the presence of IMDM medium
supplemented with 10% FBS. Culture media was replaced every
48-72 h. Differentiation was followed weekly for a period of 4
weeks. The expression of differentiation markers was determined
by real-time PCR analysis on an ABI7900HT Fast sequence
detection system using TaqMan primers (Applied Biosystems).
Matrigel assay
CPC clones were grown in endothelial growth medium (EBM
supplemented with serum and growth factors, Lonza) for 1 week
prior to plating in 24 well plates coated with Matrigel in endothelial
basal medium (EBM supplemented with 0.1% bovine serum
albumin) for 5–20 h. Tube formation potential was estimated by
measuring the number of tubes per field and tube length using
ImageJ software. Each clone was tested in 1–3 independent
experiments and at least 5 fields were counted per sample. For
some experiments, growth factor-reduced Matrigel was used and
Figure 7. Clonal heterogeneity of CPC vasculogenic properties in vivo. A–C. Vascular differentiation of SDF-1-producing CPCs in vivo. Whole
mount scan of Matrigel plugs containing no cells (control, A), low SDF-1 clone 30C1 (B) or high SDF-1 clone 11B (C). D–F: Enlargements of boxed
areas as shown. G, H: Vascular structures in CPC-seeded Matrigel plugs. Representative fluorescence microscope images of plugs containing clones
30C1 (G) or 11B (H) under identical in vivo conditions. I. Overlap of DiI-stained and GFP-expressing blood vessels. Additional images are provided in
Figure S4.
doi:10.1371/journal.pone.0024013.g007
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AMD3100 and/or vehicle.
Immunostaining and SDF-1 ELISA
For immunofluorescence, CSCs were washed and fixed in 4%
paraformaldehyde for 15 minutes. For intracellular markers, cells
were permeabilized with 0.2% Triton X-100 for 5 min. Images
were obtained using a Zeiss HBO 100 Axiovert inverted phase/
fluorescence microscope. SDF-1 protein expression levels were
determined by enzyme-linked immunosorbent assay (ELISA) in 96
well plates coated overnight with 20 mg/ml of whole cell lysates
collected from individual clones at different passages. SDF-1
recombinant protein was used as a standard.
In vivo angiogenesis assay
CPCs in monolayer culture were trypsinized and resuspended in
1 mL of stem cell media to a final concentration of ,2610
7 cells/
ml. 500 mL of cell suspension were mixed with 500 ml of growth
factor-reduced Matrigel. Control Matrigel plugs were generated
by mixing with an equal volume of stem cell media only. Following
anaesthesia with ketamine and xylazine, mice received 2
subcutaneous injections of 750 ml of control or CPC-containing
Matrigel plugs on each side of the posterior dorsum, following the
manufacturer’s recommendations. Plugs were harvested and
examined at 7 days. Prior to harvest, continuity between host
and graft vasculature was determined by intracardiac injection of
1,19-dioctadecyl-3,3,39,39-tetramethylindocarbocyanine perchlo-
rate (DiI) using a previously described method[89]. In brief, mice
were sedated, anesthetized by brief exposure to isoflurane, and
euthanized by cervical dislocation. A sternotomy was performed
and a 25 g needle was inserted into the left ventricular apex, and
the right atrium was punctured with an 18 g needle. The vascular
system was flushed through the left ventricle using 2 mL of
phosphate-buffered saline. 5 mL DiI solution was then injected
over 5 minutes, followed by 5 mL 4% paraformaldehyde. Plugs
were removed by sharp dissection, then mounted on slides for
image acquisition using either a Zeiss HBO 100 Axiovert inverted
phase/fluorescence or a LSM510 Axiovert 200 M confocal
microscope. Images were exported to.TIFF files, and Adobe
Photoshop layers was used for colocalization visualization.
Lentiviral packaging and transduction for SDF-1
Knockdown
293 T cells (7610
6) were plated in 10 cm dishes and cultured
overnight in DMEM medium + 10% FBS. The next day, cells were
transfected using with 6 mg pGIPZ, 4 mg pCMV deltaR8.2 and
2 mg pCMV-VSV-G per plate. After overnight incubation, the
culture media was replaced with fresh DMEM media + 20% FBS.
Transfection efficiency was determined by counting GFP-positive
cells. Lentivirus particles were collected from supernatants daily
beginning 24 h after transfection for 2–3 days and concentrated
prior to use. For transduction, CPC clones were plated in a 6 well
plate and lentivirus stock added. 4–6 h post-transduction, an
additional 2 ml of culture media was added and the cells incubated
overnight. At 24–48 h post-transduction cells were examined for
GFP expression. Puromycin was used to select clones carrying
lentivirus particles and efficiency of SDF-1 knockdown evaluated by
ELISA.
Quantitative realtime PCR
Total RNA was prepared from cells using RNAeasy (Qiagen) or
Trizol (Molecular Research Center, Inc) for differentiation or
stem cell PCR-arrays, respectively. RNA was quantified by UV
spectrophotometry (Nanodrop 1000, Thermo Scientific) and
reverse transcribed using an RT2 PCR Array First Strand Kit
(SA Bioscience or Applied Biosystems) with random hexamers.
cDNA samples were analyzed in duplicate using SYBR green or
TaqMan assays on an ABI Prism 7900 HT Fast Sequence
Detector System (Applied Biosystems). Ct values were normalized
to endogenous Gapdh and Actb. Normalized cts were converted to
absolute transcript levels and displayed in heatmap format using
Matlab 7.0.4 software (The MathWorks).
Global Transcription Analysis
For microarray profiling, RNA samples from 5 clones were
isolated using Trizol (Molecular Research Center, Inc.), purified
by passage through Qiagen RNeasy columns according to the
manufacturer’s instructions, and labeled for hybridization to
Affymetrix Mouse Genome 430 2.0 Arrays using standard
protocols. Briefly, arrays were pre-hybridized for 10 minutes at
45uC, after which labeled samples were added and hybridized for
16 hours at 45uC. The arrays were stained and washed according
to Affymetrix Fluidics Station 450 protocol (EukGEWS2v5_450).
Hybridization was documented using a GeneChip Scanner 3000
7G and validated with Affymetrix Microarray Suite version 5.0
(MAS 5.0) software. Pearson correlation coefficients demonstrated
high reproducibility. All data is MIAME compliant and has been
submitted to the National Center for Biotechnology Information
GEO database, accession #GSE24828.
Statistics
Microarray statistical analysis was performed using GeneSpring
7.2 software (Silicon Genetics, Redwood City, CA). Normalized
expression values were calculated by the GCRobust Multi-array
Average (GC-RMA) method. The Gene Ontology annotation tool
was used to generate functional classifications, and hierarchical
clustering was performed using Pearson correlation as a similarity
measure and average linkage as a clustering algorithm. Other
statistical analyses, including linear regression and one-way
ANOVA with Newman-Keuls and Bonferroni multiple compari-
sonstests wereperformed using GraphPad Prism 4.0cfor Macintosh
(GraphPad Software, San Diego CA USA, www.graphpad.com).
Supporting Information
Figure S1 Growth curves of 6 different cardiac progen-
itor cell clones. The growth pattern of CPC clones was followed
for a period of 6 days and doubling time was estimated to occur
every 24–48 hours. Growth patterns were similar among most
clones tested, with one exception. Values correspond to the
number of viable cells as determined by trypan blue exclusion.
(PDF)
Figure S2 Weak correlation between FLK-1 expression
and vasculogenic potential. (A) FLK1 expression was
measured by Western blot in 12 undifferentiated CPC clones as
shown and in HUVECs (ECs). (B) Quantitation of Flk 1 expression
for each clone, normalized to GAPDH. (C) Correlation (R)
between FLK-1 expression and vasculogenic index (see Table S1).
(PDF)
Figure S3 SDF-1 Knockdown in Cardiac progenitor
cells. SDF-1 was knocked down by lentiviral transduction of
CPCs using vectors expressing SDF-1 shRNA. Subclones express-
ing one of three different shRNAs (E1, H7, D8) or a scrambled
control shRNA (NS) were generated from the same parental clone.
Original viral transduction dose (particles/cell) shown on abscissa.
(PDF)
Clonal SDF-1 Levels Control CPC Angiogenesis
PLoS ONE | www.plosone.org 10 August 2011 | Volume 6 | Issue 8 | e24013Figure S4 Angiogenesis in Matrigel dermal inserts of
CPCs. Low growth factor Matrigel plugs were implanted without
cells (A), with weakly vasculogenic CPC clone 30C1 (B, D), and
with vasculogenic clone 11B (E–H). A–C and G show overlay of
brightfield and epifluorescent images. Original magnification A, B,
E, F=10x, C, D, G, H=32X.
(PDF)
Table S1 GO functions that cluster CPC clones with
similar morphology.
(PDF)
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